[{"id":"514f0a6c-a2ea-4456-9b4e-604c0c92dc8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03639194","created_at":"2023-08-12T16:10:08.643Z","updated_at":"2024-07-02T16:35:19.981Z","phase":"Phase 1","brief_title":"A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer","source_id_and_acronym":"NCT03639194","lead_sponsor":"AbbVie","biomarkers":" SEZ6","pipe":"","alterations":" ","tags":["SEZ6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e budigalimab (ABBV-181) • ABBV-011"],"overall_status":"Completed","enrollment":" Enrollment 132","initiation":"Initiation: 10/24/2018","start_date":" 10/24/2018","primary_txt":" Primary completion: 01/25/2024","primary_completion_date":" 01/25/2024","study_txt":" Completion: 01/25/2024","study_completion_date":" 01/25/2024","last_update_posted":"2024-02-09"}]